Gemtuzumab Ozogamicin
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1005 publications
Frontiers in Antibody-Drug Conjugates: Mechanisms, Design Innovations, and Clinical Applications in Targeted Cancer Therapy.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: January 17, 2026
New horizons for hope of cure in acute myeloid leukemia through immunotherapy: a narrative review.
Journal: Expert review of anticancer therapy
Published: January 08, 2026
Cancer Throughlines: 25 Years after First Approval, ADCs Continue to Pick up Steam.
Journal: Cancer discovery
Published: January 05, 2026
Targeting BCL-2 and PI3K signaling pathways enhances cytotoxicity of gemtuzumab ozogamicin against acute myeloid leukemia cells.
Journal: Biochemical and biophysical research communications
Published: December 18, 2025
Where do immunotherapies stand in management of acute leukemia in adults?
Journal: Hematology. American Society of Hematology. Education Program
Published: December 05, 2025
DNA Damage Sensing and TP53 Function as Modulators of Sensitivity to Calicheamicin-Based Antibody-Drug Conjugates for Acute Leukemia.
Journal: Cancers
Published: November 26, 2025
Cladribine, high-dose cytarabine, plus gemtuzumab ozogamicin (CLAG-GO) as frontline intensive therapy for fit patients with core-binding factor acute myeloid leukemia.
Journal: Leukemia & lymphoma
Published: October 31, 2025
Recent insights and clinical issues in acute myeloid leukemia in older adults
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: October 01, 2025
Curative strategies for high-risk acute promyelocytic leukemia.
Journal: Current opinion in oncology
Published: October 01, 2025
Budget Impact of Venetoclax for Newly Diagnosed Patients with Acute Myeloid Leukemia Aged ≥ 75 Years or with Comorbidities Precluding Intensive Chemotherapy in the United States.
Journal: Advances in therapy
Published: September 29, 2025
Last Updated: 04/28/2026